According to one aspect, the disclosure provides a composition for coating a tablet, including an alginate, a natural oil, a modified starch, and a cellulose derivative. According to another aspect, the disclosure provides a method for enteric coating of a tablet, including the step of coating a tablet with a composition including an alginate, a natural oil, a lecithin, and a cellulose derivative. The composition for coating a tablet according to an embodiment of the disclosure is safe as a naturally-derived ingredient and has excellent ability of coating because it can effectively coat even the edge of the tablet. In addition, the composition for coating a tablet according to an embodiment of the disclosure can implement an enteric coating, and thus has excellent heartburn suppression effect.

Compounds of formula (I), wherein A, R, W, Q, n, and m have the meaning according to the claims, can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease. ##STR00001##

A pharmaceutical or nutraceutical composition, contains a) a core a), containing a pharmaceutical or a nutraceutical active ingredient and b) a coating layer b), containing a mixture of 80 to 96% by weight of a water-insoluble (meth)acrylate polymer and 4 to 20% by weight of guar gum, wherein the water-insoluble (meth)acrylate polymer contains polymerized units of more than 95 and up to 100% by weight C.sub.1-C.sub.4-alkyl esters of acrylic acid or of methacrylic acid and less than 5% by weight of acrylic acid or methacrylic acid.

An implantable and retrievable medical device is provided. The device may be implanted in and extracted from a patient and the device is adapted to house and deliver donor cells or other drugs. The device comprises a hollow core having a volume for receiving cells and a plurality of layers surrounding the core. The layers comprise various materials suitable for enhancing immunoprotection and for promoting vascular growth into the device.

Provided is a method of controlling local release of target compounds by patterning a hydrogel carrying a bone morphogenetic protein or anticancer drug as the target compounds onto an electrospun nanoporous membrane. The hydrogel is capable of controlling local release of the bone morphogenetic protein or anticancer drug as a carrier of the bone morphogenetic protein or anticancer. And the electrospun nanoporous membrane performs a basic function of the membrane of preventing infiltration of connective tissue. Thus, there is an advantage in that the hydrogel patterned nanoporous membrane can facilitate generation of controlled bone in a local region and degradation of cancer in a local region.

Disclosed is a capsule, tablet or pill comprising a formulation at least two of the fat-soluble vitamins vitamin A, vitamin D, vitamin E and vitamin K; and one or more kinds of medium-chain triglyceride; also disclosed are foods, drinks and pharmaceutical compositions comprising the capsule, tablet or pill; and methods of treatment of a patient comprising administration of an effective amount of the capsule, tablet or pill. The capsule, tablet or pill is particularly, but not exclusively, suitable for use in treating cystic fibrosis patients.

Controlled release dosage forms are described herein. The controlled release formulations described herein provide prolonged delivery of high dose drugs that are highly water soluble and highly hygroscopic. In specific embodiments, controlled release dosage forms for delivery of a drug selected from GHB and pharmaceutically acceptable salts, hydrates, tautomers, solvates and complexes of GHB. The controlled release dosage forms described herein may incorporate both controlled release and immediate release formulations in a single unit dosage form.

The present invention relates to an improved gelatinous coated dosage form having two end regions coated with gelatinous materials and an exposed circumferential band. Openings are provided in at least the exposed band to reveal the core material. The invention also relates to methods for manufacturing such gelatinous coated dosage forms.

The present invention provides a film coating composition for a solid preparation that is easy to take. The present invention also provides a solid preparation that is easy to take. A film coating composition according to an embodiment of the present invention contains a polyvinyl alcohol-polyethylene glycol graft copolymer and a thickening agent. The thickening agent may be composed of one or more substances that are selected from the group consisting of xanthan gum, locust bean gum, pectin, carrageenan, guar gum, gellan gum, and carboxy vinyl polymer.

The present invention relates to the therapeutic use of compositions containing 5-aminolevulinic acid for the local treatment of inflammatory bowel disease, including but not restricted to ulcerative colitis and Crohn's disease.